by aisla@raikee.fi | Sep 19, 2018 | News
Desentumin joukkorahoituskierros käynnistyi 17.9.2019 Desentum on aloittamassa kliiniset tutkimukset ensimmäisellä immunoterapeuttisella tuotteellaan, DM-101:llä, joka on suunnattu koivuallergian hoitoon. Tuotteella pyritään koivuallergian siedätyshoidon merkittävään...
by aisla@raikee.fi | Nov 29, 2017 | News
Desentum is progressing towards clinical stage with its first immunotherapeutic product targeting birch pollen allergy. It has raised approx. EUR 2.3 million in a crowd funding campaign arranged by a Finnish investment service company Kansalaisrahoitus. The funds...
by aisla@raikee.fi | Oct 5, 2017 | News
Desentum is approaching first-in-man clinical trials with its lead product candidate, a modified hypoallergen aimed for an immunotherapeutic treatment of birch pollen allergy. The birch pollen hypoallergen has shown promise in laboratory tests. Next, it needs to be...
by aisla@raikee.fi | Jun 14, 2017 | News
The annual congress of the European Academy of Allergy and Clinical Immunology will be in Helsinki in June 17-21. Desentum has presentations in two Oral Abstract Sessions. Espoo, Finland, 14 June 2017 – One of the world’s biggest scientific meetings in the...
by aisla@raikee.fi | Jan 23, 2017 | News
Desentum secured funding to advance their treatment targeting birch pollen allergy. ESPOO, Finland, 23 January 2017– Today, Desentum, a biopharmaceutical company developing next generation immunotherapy to fight allergies, announced that it has completed a Series...
by aisla@raikee.fi | Dec 5, 2013 | News
VTT Technical Research Center of Finland received an innovation prize for the technological development work behind an allergy vaccine. The award ceremony was held in Brussels in December 2013. VTT’s patents are based on application of gene technology to...
